Abstract
7-yl)-3-ethynyl-5-hydroxy-methyl-tetrahydro-furan-3,4-diol is a potent inhibitor of 23 dengue virus (DENV), with EC 50 and CC 50 of 0.7 µM and > 100 µM, respectively. Here we 24 describe the synthesis, structure-activity relationship, and antiviral characterization of the 25 inhibitor. In an AG129 mouse model, a single-dose treatment of DENV-infected mice with 26 the compound suppressed peak viremia, and completely prevented death. Mode-of-action 27 analysis using a DENV replicon indicated that the compound blocks viral RNA synthesis. 28 Recombinant adenosine kinase could convert the compound to a monophosphate form. 29 Suppression of host adenosine kinase, using a specific inhibitor (iodotubercidin) or siRNA, 30 abolished or reduced the compound's antiviral activity in cell culture. Studies in rats 31 showed that 14 C-labeled compound was converted to mono-, di-, and triphosphate 
75
Here we report the synthesis, structure-activity relationship (SAR), and biological 76 characterization of a number of nucleosides with the general structure A which led to the 77 identification of compound 1 (Fig. 1) . Biochemical experiments showed that compound 1 78 could be converted to the monophosphate by a recombinant human adenosine kinase. It was previously shown that adenosine with a ribose 2'-C-alkyl substitution could 11 be deaminated by cellular adenosine deaminase to an inosine derivative (6), which was not 220 active against DENV (data not shown). Since this metabolic pathway is also potentially 221 relevant for compound 11, we substituted the adenine C-7 nitrogen with a carbon 222 (compound 1; Table 3 ). This modification slightly improved the anti-DENV activity, but 223 significantly reduced the cytotoxicity (CC 50 >100 µM). We further explored the possible 224 substitutions at the adenine C-7 position (Table 3) . When the C-7 proton was substituted 100 µM, the highest tested concentration (Fig. 2B ). 
245
( Fig. 2C) . Western blotting result showed that less viral NS3 protein was expressed when 246 the transfected cells were treated with the compound (Fig. 2D) the recombinant deoxycytidine kinase did not phosphorylate compound 1 (data not shown).
267
The results suggest that adenosine kinase is responsible for the phosphorylation of 268 compound 1.
269
Effects of adenosine kinase on antiviral activity in cell culture. We took two 
292
Conversion of compound 1 to mono-, di-, and triphosphate forms in rats. We 293 examined the phosphorylation profile of compound 1 in rats using a 14 C-labeled compound.
294
The compound was 14 C-labeled at the C-2 position of the adenine base. After dosing the 295 rats with 5 mg/kg of compound 1 intravenously or with 25 mg/kg orally, nucleoside 296 metabolites were extracted from plasma and blood cells, respectively. FPLC analysis of 297 these extracts showed that only the parent compound was detected in the plasma (Fig. 5A) , 298 whereas the mono-, di-, and triphosphate derivatives, together with the parent compound, 299 were detected in the blood cells (Fig. 5B ). The results demonstrate that compound 1 can be 300 converted into the corresponding triphosphate form in vivo. shows a potent in vivo efficacy against flavivirus after a single-dose treatment.
338
Our results strongly indicate that compound 1 exerts its antiviral activity through 339 RNA chain termination. This conclusion is supported by three lines of evidences. First, 340 using a DENV replicon, we showed that the compound suppressed viral RNA synthesis; it 341 did not inhibit viral translation (Fig. 2) . Second, we previously showed that the 342 triphosphate form of compound 1 was able to directly inhibit RNA elongation catalyzed by results that after orally dosing compound 1 in rats, the compound was converted to the 349 mono-, di-, and tri-phosphate forms in blood cells (Fig. 5 ).
350
The nucleoside-based approach for antiviral development faces several challenges. compound to its monophosphate form (Fig. 3) . Inhibition of adenosine kinase using a 366 specific inhibitor (iodotubercidin) or siRNA, abolished or reduced the compound's 367 antiviral activity (Fig. 4) were orally dosed once with the indicated amount of compound 1 at 12 h post-infection.
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The peak viremia on day 3 p.i. was measured by plaque assay. Symbol "*" indicates that 
